Pacheco OE, Grant VS

Language: Spanish
References: 14
Page: 93-98
PDF size: 780.78 Kb.

ABSTRACT

The increasing rate of heart failure (HF) with preserved ejection fraction has received more attention from the international medical society. The high prevalence of cardiovascular diseases has made of HF a common diagnosis in our societies. It is important to differentiate symptoms such as edema or shortness of breathing from other non cardiovascular causes such as COPD, obesity, anemia, medications. The findings of high levels of specific biomarkers, symptoms related to HF, and cardiovascular structure and functional abnormalities are the cornerstone for the diagnosis. Unfortunately there is limited direct evidence to support a specific drug regimen to treat HF with preserved ejection fraction.

REFERENCES

1. 3. Dan L Longo Dennis L Kasper et al: Harrison Principios de Medicina Interna. Editorial McGraw Hill. Decimoctava edición, 2012. Vol 2 1901-1904.

2. Senni M J Paulus W Gavazzi A et al: New Strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes, European Society of Cardiology. European Heart Journal 35, 2797-2811, 2014.

3. Owan TE Hodge DO Herges RM et al: Trends in prevalence and outcome of heart failure with preserverd ejection fraction, New England Journal of Medicine 355:251, 2006.

4. Kitzman DW Little WC: Left ventricle diastolic dysfunction and prognosis, Circulation 125: 743, 2012.

5. Lam CSP Roger VL Rodeheffer RJ et al: Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction: From Olmstead County, Minnesota. Circulation 115:1982, 2007.

6. Little WC Zile MR: HFPEF: Cardiovascular abnormalities not just co-morbidities, Circ Heart Fail 5:669, 2012.

7. Little WC Zile MR Klein A et al: Effect of losartan and hydrochlorothiazide on exercise tolerance in extertional hypertension and left ventricular diastolic dysfunction, American Journal of Cardiology 98:383, 2006.

8. Zile MR Gaasch WH Anand IS et al: Mode of death in patients with heart failure and preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection fraction Study (I-Preserve) trial, Circulation 121:1393, 2010.

9. Douglas L Mann P Zipes Petter Libby et al: Braunwald’s Heart Disease. A textbook of Cardiovascular Medicine. El Sevier. Décima Edición 2015, pag 557

10. A Borlaug S Colucci B Yeon: Treatment and prognosis of heart failure with preserved ejection fraction. Up to date, 2015.

11. Aurigemma GP Gaasch WH. Clinical Practice. Diastolic heart failure. New England Med 2004; 351:1097

12. Sharma K Kass DA. Heart failure with preserved ejection graction: mechanisms, clinical features, and therapies. Circ Res 2014; 115:79

13. Yancy CW Jessup M Bozkurt, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147

14. Owan TE Hodge DO Herges RM et al: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006